Skip to main content

Table 2 Summary of 20 benign lesions in 20 patients

From: Comparison of Tc-99m maraciclatide and Tc-99m sestamibi molecular breast imaging in patients with suspected breast cancer

Benign lesion number

Histopathology

L/B ratio

Assessment

99mTc sestamibi

99mTc maraciclatide

99mTc sestamibi

99mTc maraciclatide

1

ADH

1.24

1.28

3

3

2

ADHa

Not seen

1.34

1

4

3

Benign fibrocystic changes

Not seen

Not seen

1

2

4

Benign fibrocystic changes

Not seen

Not seen

1

1

5

Benign fibrocystic changes

Not seen

Not seen

1

2

6

Benign fibrocystic changes

Not seen

Not seen

1

1

7

Benign fibrocystic changes

Not seen

Not seen

1

2

8

Benign fibrocystic changes

Not seen

Not seen

1

1

9

Fibroadenoma

1.52

1.35

3

3

10

Fibroadenoma

Not seen

Not seen

1

2

11

Fibroadenoma

Not seen

Not seen

1

1

12

Fibroadenoma

Not seen

Not seen

1

2

13

Fibroadenoma

1.24

1.13

3

4

14

Fibroadenoma

1.14

1.25

2

3

15

Fibroadenomab

1.12

1.11

4

4

16

Inflammatory tissue

1.25

1.36

4

4

17

Intramammary lymph node

1.14

Not seen

4

2

18

Papilloma

Not seen

Not seen

2

2

19

Papilloma

1.07

1.13

2

2

20

PASH

2.35

2.76

2

2

  1. ADH atypical ductal hyperplasia, PASH pseudoangiomatous stromal hyperplasia
  2. aPatient with invasive ductal carcinoma had ADH diagnosed in the contralateral breast
  3. bPatient with invasive ductal carcinoma had a fibroadenoma in the ipsilateral breast